Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00455650 · ClinicalTrials.gov registry record · NA
Study of the Effects of Mecamylamine and Varenicline in Schizophrenia
A NA study of Cognition in Schizophrenia, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 89
- Enrollment target
- 1
- Study location
NCT00455650 is a NA study of Cognition in Schizophrenia that has completed, run by Massachusetts General Hospital. The registered enrollment target is 89 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00455650, a NA study of Cognition in Schizophrenia, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 89 participants
- Enrollment target
- 1
- Study location
Study Summary
We are conducting this study to find out if blocking or partially stimulating the effects of nicotine in the brain can affect memory and concentration. Nicotine is the addictive drug found in tobacco products. Our subjects will be people with and without mental illness (schizophrenia), smokers and non-smokers. We will use a medication called mecamylamine (Inversine) to block the effects of nicotine on the brains of our subjects. We will also use a medication called varenicline (Chantix) to partially increase the effects of nicotine on the brains of our subjects. This study also uses a placebo, a pill that does not have any active ingredients but looks exactly like the mecamylamine and varenicline pills. We will compare the effects of giving mecamylamine or placebo to people who have schizophrenia and people who do not have schizophrenia. We know that people with schizophrenia smoke heavily and find it harder to stop smoking than most other people do. Studies have shown that people with schizophrenia may smoke more because nicotine helps their concentration and memory. We are interested in helping people with schizophrenia smoke less. Mecamylamine blocks the parts of the brain that react to nicotine and varenicline partially stimulates and partially blocks the parts of the brain that react to nicotine. Both medications may decrease the effects that smoking has on the body.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Varenicline
- DRUG Mecamylamine
Study Locations (1)
Massachusetts
- Freedom Trail Clinic, Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2007-03 |
| Est. Completion | 2013-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00455650
The ClinicalTrials.gov registry entry for NCT00455650 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cognition in Schizophrenia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00455650 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00455650 about?
NCT00455650 is a clinical study titled "Study of the Effects of Mecamylamine and Varenicline in Schizophrenia". We are conducting this study to find out if blocking or partially stimulating the effects of nicotine in the brain can affect memory and concentration. Nicotine is the addictive drug found in tobacco products. Our subjects will be people with and without mental illness (schizophrenia), smokers and n...
What is the current status of trial NCT00455650?
This trial is currently completed. It is a NA study. The enrollment target is 89 participants. The study started on 2007-03. Estimated completion is 2013-01.
What conditions does trial NCT00455650 study?
This clinical trial studies the following conditions: Cognition in Schizophrenia.
What interventions are being tested in trial NCT00455650?
The interventions under investigation include: Placebo (DRUG), Varenicline (DRUG), Mecamylamine (DRUG).
Who is sponsoring clinical trial NCT00455650?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00455650 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognition in Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.